INTRODUCTION
In silico docking methods and structure-based drug design are useful bioinformatics tools for identifying new agents against tuberculosis. In our previous study 1 , a newly developed FRIGATE docking algorithm 2 was utilized for a virtual screen of several million small molecules against the species-specific surface loop of Mtb DUTPase (EC 3.6.1.23; Rv2697) enzyme 3, 4 . As a result, we reported the identification of 10 new compounds, active against Mtb H 37 Rv in vitro. The lowest minimal inhibitory concentration (MIC) was measured for TB8 compound (1 µg/mL, 3.7 µM), a pyridopyrimidine derivative. To optimize the structure of TB8 compound, more than 100 derivatives were synthesized, in vitro evaluated and the structure-activity relationship was analyzed.
One of the derivatives, TB820 molecule (4-oxo-2-(pyrrolidin-1-yl)-pyrido[1,2-a]pyrimidine-3-carbaldehyde) was chosen in this study for further modification in order to improve its therapeutic efficacy by using advanced drug delivery system (DDS).
Targeted delivery of antitubercular drugs into macrophages, which provide the intracellular survival of the mycobacteria, has crucial pharmaceutical benefits. The phagocytic uptake process of macrophages is highly efficient due to the expression of specific receptors such as the IgG receptor and complement receptors 5 . DDS can be engineered to achieve enhanced cellular uptake and bioavailability, controlled drug release and reduced side effects. In this paper we report the design of a new type of advanced DDS, where the antitubercular agent is conjugated to a tuftsin peptide derivative and encapsulated into PLGA nanoparticles. Tuftsin is a natural phagocytosis stimulating peptide produced by enzymatic cleavage of the Fc-domain of the heavy chain of IgG. During the past decade, a new group of sequential oligopeptide carriers has been developed in our laboratory:
oligotuftsin derivatives consisting of a pentapeptide unit TKPKG 6, 7 . In this study, the TKPKG peptide was elongated with palmitic acid to enhance the lipophilicity, membrane affinity and encapsulation efficacy. Nanoencapsulation into lactic and glycolic acid (PLGA) copolymers is an efficient method for sustained controlled release and intensively explored for antitubercular therapy 8 . These biodegradable and biocompatible polymer-based nanoparticles have the ability to essentially modify the biodistribution of an active compound and the release rate can be controlled by the size and composition of the particles 9 . PLGA is approved by the US Food and Drug Administration (FDA) for clinical use and it can be utilized in oral formulation 10 .
Synthesis and characteristics of peptide-conjugated and PLGA encapsulated TB820 is described in this work. In vitro antitubercular efficacy of the conjugate is compared to its cytotoxicity and hemolytic activity. Furthermore, in vivo chemotherapeutic effect of the orally administered PLGApT820 compound in a guinea pig infectious model is presented.
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MATERIALS AND METHODS
Synthesis and characterization of PLGA encapsulated pal-T5(TB820) 2
The TB820 compound was conjugated to a palmitoylated tuftsin derivative. First protected tuftsin (TKPKG, T5) was produced manually by solid-phase peptide synthesis using Boc/Bzl strategy.
Palmitic acid was coupled to the N-terminus of the peptide. The N  -Fmoc protecting groups of the side chain of Lys residues were selectively removed and free amino groups were reacted with Bocaminooxyacetic acid. After Boc deprotection, peptide was removed from the resin with liquid HF in the presence of scavengers. Palmitoylated aminooxi-peptide was then allowed to react with the TB820 compound in solution and the precipitated conjugate was filtered and purified. Final product pal-T5(TB820) 2 (pT820) was characterized by analytical RP-HPLC, ESI-MS and amino acid analysis.
PLGA nanoparticles were prepared by the nanoprecipitation (solvent exchange) method, detailed previously 11 . Briefly, PLGA and pT820 conjugate were dissolved in acetone and added dropwise to an aqueous solution of Pluronic 12700. The resulting nanoparticle suspension was centrifuged, purified by dialysis and freeze-dried. Drug content of the lyophilized powder was determined by amino acid analysis.
In vitro tests
In vitro antitubercular activity of the compound was determined against Mycobacterium tuberculosis H 37 Rv (ATCC 27294) and multiresistant M. tuberculosis (MDR A8) by serial dilution method in Sula semi-synthetic medium. The minimal inhibitory concentration (MIC) was determined after incubation at 37 o C for 28 days. The activity of the tested compounds was confirmed using colony forming unit (CFU) enumeration by subculturing from the Sula medium onto drug-free Löwensten-Jensen solid medium (37 o C, 28 days).
In vitro cytotoxicity was evaluated on human peripheral blood mononuclear cells (PBMC), prepared from peripheral blood of healthy volunteers using Ficoll-Hypaque density gradient centrifugation method. The pT820 conjugate was added to the cells to give 0.5 M -200 M final concentration. Cells were incubated at 37 o C for 4 hours, then cell viability was tested using MTT (3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.
5
In vitro hemolytic activity of pT820 was determined on human erythrocytes. Red blood cell suspension was incubated with the compounds (0.5 M -200 M final concentration) for 4 hours at 37 o C and after centrifugation, the absorbance of the supernatant was measured at λ=450 nm.
In vivo evaluation
Inbred, female guinea pigs aged 6 weeks at weight 400-500 g were housed four per cage and allowed free access to water and to standard pellet diet. All animal experiments were approved by the Hungarian Scientific Ethical Committee on Animal Experimentation (No: 22.1/3720/003/2009).
To study the in vivo toxicity, animals were administered orally twice a week with 50 mg/kg bw of PLGA-pT820 (n = 3 for the treatment group). To monitor the side effects, changes in body weight were determined weekly and after 7 weeks of administration, animals were euthanized and diagnostic autopsy was evaluated.
In vivo antitubercular effect of the PLGA-pT820 compound was evaluated on Mtb infected guinea pigs (n = 6 for treatment and 6 for control group). First, guinea pigs were infected with Mtb H 37 Rv suspension by intramuscular injection. Infection was followed by sacrificing one animal each week and performing histopathological analysis from the organs. Chemotherapy was started 3 weeks after infection. PLGA-pT820 compound (50 mg/kg bw) was suspended in 1 mL sterile water and administrated orally twice a week. Control animals were administered of 1 mL sterile water with the same frequency. After 12 weeks of chemotherapy, animals were euthanized by ketamine (40 mg/kg bw) and dexmedetomidine (Dexdomitor, 0.5 mg/kg bw).
To count the number of bacteria in the organs, a portion of lung, spleen, liver and kidney were resected and homogenized in Sula media. 1:1000 dilutions of the homogenates were plated onto Löwenstein-Jensen solid media and after 8 weeks of incubation CFU was enumerated. For histopathological analysis, lung, spleen, liver, kidney, inguinal lymph nodes and heart muscle of each animal were removed and fixed in 8% neutral buffered formalin for 24 hours at room temperature. Tissue specimens were dehydrated in a series of ethanol and xylene baths and embedded in paraffin wax. Sections (3-4 μm) were stained with haematoxylin and eosin (HE.). For in situ visualization of the acid-fast bacilli Ziehl-Neelsen (ZN) staining method was applied on similarly pre-treated sections.
RESULTS AND DISCUSSION
Palmitoylated tuftsin derivative was used as a carrier for the TB820 compound. Chemical structure and homogeneity of the conjugate was proved by mass spectrometry (M mo (calculated) = 1362.8; M mo (found) = 1362.8), analytical RP-HPLC and amino acid analysis. Structure and mass spectra of the pT820 conjugate is given in FIGURE 1. The pT820 conjugate was encapsulated into PLGA nanoparticles by nanoprecipitation method. The encapsulation efficacy was up to 83%. The drug content of the PLGA-pT820 nanoparticles was 20.2%.
In Vitro Antitubercular effect, cytotoxicity and hemolytic activity
Antitubercular effect of the compounds was measured against Mtb H 37 Rv strain. The MIC value of the TB820 molecule was 1 µg/mL (4.1 µM), while the MIC value of the pT820 conjugate was 5 µg/mL (3.7 µM). From this result we can conclude that the chemical modification of the TB820 molecule did not influence its antimicrobial efficacy. The antitubercular effect of the compounds was also tested on multiresistant Mtb (MDR A8) strain. The MIC value was 1 µg/mL (4.1 µM) for the TB820 molecule and 10 µg/mL (7.4 µM) for the pT820 conjugate. Before in vivo experiments, we assayed the cytotoxicity and hemolytic activity in vitro. We found that the pT820 conjugate was not cytotoxic to human PBMC and to human erythrocytes even at the highest concentration (IC 50 > 200 µM; HC 50 > 200 µM).
In Vivo toxicology and chemotherapeutic effect of PLGA-pT820
To monitor the toxicity of PLGA-pT820, 3 guinea pigs were administered orally twice a week with a dose of 50 mg/kg bw. During the experiment animals maintained a constant weight gain and no symptoms, related to compound toxicity were observed. After 7 weeks of administration of PLGApT820, animals were euthanized and diagnostic autopsy proved that no significant malformations on the tissues occurred.
To study the chemotherapeutic effect, guinea pigs were infected intramuscularly with Mtb H 37 Rv suspension. After 3 weeks of incubation, the animals were randomly divided into two groups. Six guinea pigs were treated orally with PLGA-pT820 (50 mg/kg bw, twice a week for a period of 12 weeks). Six animals receiving sterile water with the same frequency were employed as controls. As As a summary of this study we can conclude that a new type of peptide based drug delivery system was applied for the TB820 molecule with relevant chemotherapeutic efficacy against experimental tuberculosis. Palmitoylated tuftsin peptide conjugate of TB820 found to be effective against susceptible and multiresistant Mtb strains with a relatively high in vitro selectivity (IC 50 and HC 50 was more than 50-times higher than MIC). The pT820 conjugate was entrapped into PLGA nanoparticles with high encapsulation efficacy. The PLGA-pT820 compound was not toxic to guinea pigs at the therapeutic concentration. Guinea pigs were infected with virulent Mtb H 37 Rv and treated with PLGA-pT820. Untreated control animals show numerous severe lesions with extensive 9 parenchymal involvement. These signs of infection were characterized by the evidence of necrosis with intralesional mineralization, thus reflecting progression of the disease. In contrast, PLGA-pT5i treated animals had considerably decreased inflammation and minimal granulomatous involvement.
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